| Name | Title | Contact Details |
|---|---|---|
Daymon Smith |
Chief Product and Technology Officer | Profile |
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. FibroGen’s research team is committed to discovering novel therapies in areas of major unmet medical need. Our goal is to continue to provide pipeline candidates supported by rigorous data in well-characterized therapeutic settings. All of FibroGen`s therapeutic candidates have been internally developed based on FibroGen`s pioneering research in two important areas of biology, hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF).
Pet First Health Care is a Jeffersonville, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PG Drives Technology is a Anaheim, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Community Health Partnership of Illinois (CHP) is a non-profit organization that provides high quality, patient centered healthcare to uninsured, underserved, migrants, seasonal agricultural workers and their families across rural and urban communities...
Maverick Therapeutics is pioneering the next generation of redirected T-cell targeted immunotherapies. Mavericks highly innovative platform, COBRA™, is the most advanced bispecific T-cell engaging platform in its class, designed to safely target solid tumors with highly specific and potent activity.